Hypothalamic–pituitary hormone

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

Albany Molecular Research Inc. (AMRI) Named Exclusive API Supplier for Recently Approved Acne Treatment

Retrieved on: 
Friday, October 30, 2020

Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with Winlevi.

Key Points: 
  • Hypothalamic-pituitary-adrenal (HPA) axis suppression may occur during or after treatment with Winlevi.
  • In the PK trial, HPA axis suppression was observed in 1/20 (5%) of adult subjects and 2/22 (9%) of adolescent subjects at Day 14.
  • All subjects returned to normal HPA axis function at follow-up four weeks after stopping treatment.
  • Conditions which augment systemic absorption include use over large surface areas, prolonged use, and the use of occlusive dressings.

Adrenal Insufficiency Fund Opens at the HealthWell Foundation

Retrieved on: 
Monday, September 14, 2020

According to the National Adrenal Diseases Foundation (NADF), adrenal insufficiency is a life-threatening disorder caused by impaired secretion of vital hormones produced in the cortex of adrenal glands, small glands located just above the kidneys.

Key Points: 
  • According to the National Adrenal Diseases Foundation (NADF), adrenal insufficiency is a life-threatening disorder caused by impaired secretion of vital hormones produced in the cortex of adrenal glands, small glands located just above the kidneys.
  • This condition can be caused by primary destruction or dysfunction of the adrenal glands (Primary Adrenal Insufficiency, PAI) or impairment of the hypothalamic-pituitary-adrenal axis (Secondary Adrenal Insufficiency, SAI).
  • "We are honored to work with the HealthWell Foundation to provide financial assistance for those who need it most and to raise awareness about adrenal insufficiency.
  • The fund for adrenal insufficiency patients will support the financial needs of the community," said Kalina Warren, NADF Board President.